Carbamazepine, lamotrigine, levetiracetam and valproic acid in dried blood spots with liquid chromatography tandem mass spectrometry; method development and validation

Linder, Camilla; Hansson, Anna; Sadek, Sara; Gustafsson, Lars L.; Pohanka, Anton

doi:10.1016/j.jchromb.2017.11.005

Cited by 33 publications

(46 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of the studies that used the DPS method demonstrated that C dps could be converted to C p without any changes. In the studies of adults that used the DBS method, C dbs was slightly higher than C p . Linder et al found that C p from venous and capillary blood was well correlated with C dbs ( r 2 = 0.9532), and C p was 15% lower than C dbs within an Hct level of 30%‐50%.…”

Section: Aed Concentration Measurement Using Dbs or Dpsmentioning

confidence: 99%

“…In the studies of adults that used the DBS method, C dbs was slightly higher than C p . Linder et al found that C p from venous and capillary blood was well correlated with C dbs ( r 2 = 0.9532), and C p was 15% lower than C dbs within an Hct level of 30%‐50%. In addition, Aburuz et al reported that C p was slightly lower (2%‐7%) than C dbs ; however, there was no significant difference.…”

Section: Aed Concentration Measurement Using Dbs or Dpsmentioning

confidence: 99%

“…An analytical method using DPS sampling was developed and demonstrated a fair result ( r = 0.971) ; other methods that used DBS sampling also demonstrated a good correlation between C dbs and C p ( r > 0.995) . A recent clinical validation involving 15 patients with epilepsy found that C dbs was comparable with C p within an Hct level of 30%‐50% ( r 2 = 0.9927) . Further validation among a larger sample of patients with epilepsy is required before its application in clinical practice and TDM.…”

Section: Aed Concentration Measurement Using Dbs or Dpsmentioning

confidence: 99%

“…Pohanka et al reported that C p of valproic acid was 27% higher than C dbs , and higher Hct levels had a greater impact. In another study involving 13 patients with epilepsy, C dbs of valproic acid was 35% higher than C p . Kong et al developed the following equation to estimate C p from C dbs using the Hct level and ratio of red blood cells to plasma: C p = (0.92 × C dbs /[1 ‐ (0.96 × Hct)]) ‐ 12.48 μg/mL.…”

Section: Aed Concentration Measurement Using Dbs or Dpsmentioning

confidence: 99%

See 3 more Smart Citations

Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti‐epileptic drugs

Min

Ryu

Chang

2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Anti‐epileptic drugs (AEDs) have various pharmacokinetic profiles, inter‐individual variabilities, high possibilities of drug‐drug interactions and narrow therapeutic indices. To provide optimal treatment for patients, therapeutic drug monitoring (TDM) is necessary. However, TDM requires sufficient quantities of blood samples to measure drug concentrations. Therefore, TDM could be a burden, particularly in paediatric cases. A good alternative that overcomes these disadvantages is the dried blood spot (DBS) method, which is simple, convenient to use and less invasive, requiring a lower quantity of blood than traditional blood sampling methods. However, the DBS method is affected by haematocrit (Hct) levels to varying extents depending on the drug properties. In addition, different papers with varying characteristics are available for use when applying the DBS method. Therefore, it has not yet been applied to TDM in clinical practice. To achieve this, several steps are required, including method development, method validation and clinical validation. Currently, the development status of the DBS method is different for each AED and unclear. Therefore, we assessed the development status of the following 19 AEDs in 26 studies: lamotrigine, valproic acid, levetiracetam, phenytoin, topiramate, carbamazepine, carbamazepine epoxide, gabapentin, phenobarbital, pregabalin, clobazam, clonazepam, ethosuximide, felbamate, monohydroxycarbamazepine, nitrazepam, rufinamide, vigabatrin and zonisamide. Among them, carbamazepine, lamotrigine, topiramate and valproic acid have been developed such that they are nearly available for TDM. In addition, Whatman 903 Protein Saver Cards and concentration analysis by liquid chromatography with triple quadrupole mass spectrometer were used most often.

show abstract

Section: Aed Concentration Measurement Using Dbs or Dpsmentioning

confidence: 99%

Section: Aed Concentration Measurement Using Dbs or Dpsmentioning

confidence: 99%

Section: Aed Concentration Measurement Using Dbs or Dpsmentioning

confidence: 99%

Section: Aed Concentration Measurement Using Dbs or Dpsmentioning

confidence: 99%

See 2 more Smart Citations

Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti‐epileptic drugs

Min

Ryu

Chang

2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Urine and blood are the most commonly used samples in clinical setting, while the rest of the listed options are usually regarded as alternatives. Less conventional matrices include dried blood spots with capillary blood, which is also used for neonatal metabolic disease screening and has recently gained more attention in clinical and forensic toxicology also for other applications . Advantages of these alternative techniques are their longer detection time window and the less invasive sample collection and easier storage and shipping .…”

Section: Analyticsmentioning

confidence: 99%

Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication

Grafinger

Liechti

Liakoni

2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

New psychoactive substances (NPS) have emerged worldwide in recent years, posing a threat to public health and a challenge to drug policy. NPS are usually derivatives or analogues of classical recreational drugs designed to imitate their effects while circumventing regulations. This article provides an overview of benefits and limitations of analytical screening in managing patients presenting with acute NPS toxicity. NPS typically cannot be analytically identified with the usual immunoassay tests. To detect NPS using an immunoassay, antibodies specifically binding to the new structures would have to be developed, which is complicated by the rapid change of the NPS market. Activity‐based assays could circumvent this problem since no prior knowledge on the substance structure is necessary. However, classical recreational drugs activating the same receptors could lead to false positive results. Liquid or gas chromatography coupled with mass spectrometry is a valuable NPS analysis tool, but its costs (e.g. equipment), run time (results usually within hours vs minutes in case of immunoasssays) and the need for specialized personnel hinder its use in clinical setting, while factors such as lack of reference standards can pose further limitations. Although supportive measures are sufficient in most cases for adequate patient management, the detection and identification of NPS can contribute significantly to public health and safety in cases of e.g. cluster intoxications and outbreaks, and to the investigation of these novel compounds' properties. However, this requires not only availability of the necessary equipment and personnel, but also collaboration between clinicians, authorities and laboratories.

show abstract

Increasing Complexity to Simplify Clinical Care: High Resolution Mass Spectrometry as an Enabler of AI Guided Clinical and Therapeutic Monitoring

Yee

Drum

2020

Advanced Therapeutics

View full text Add to dashboard Cite

Clinical care increasingly relies on individualized, highly multidimensional data for patient phenotyping. This review focusses on two technologies which are contributing to this trend and, in their mutual overlap, may provide a novel and powerful contribution to future clinical care. Artificial intelligence (AI), in particular the technique of deep learning, is steadily making inroads to clinical care and has demonstrated the ability to extract clinically relevant features from complex datasets. Likewise, mass spectrometry (MS), in particular high-resolution MS, is gaining the ability to provide highly multidimensional datasets from patient samples with the quality necessary for clinical decision making. The convergence of these trends has resulted in the nascent application of deep learning analytics to high resolution mass spectra. Due to the large volumes of content provided by high resolution mass spectra and the ability of multilayer neural networks to extract subtle features from complex datasets, future integration of their mutual application is identified as a research area of high priority for clinical care. Factors are identified that have contributed to historical progress for each technology and recommendations are provided to accelerate the mutual application of deep learning and mass spectrometry techniques to patient care.

show abstract

Carbamazepine, lamotrigine, levetiracetam and valproic acid in dried blood spots with liquid chromatography tandem mass spectrometry; method development and validation

Cited by 33 publications

References 19 publications

Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti‐epileptic drugs

Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti‐epileptic drugs

Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication

Increasing Complexity to Simplify Clinical Care: High Resolution Mass Spectrometry as an Enabler of AI Guided Clinical and Therapeutic Monitoring

Contact Info

Product

Resources

About